TY - JOUR
T1 - Thalidomide Neuropathy
AU - Crawford, C. L.
AU - Vogelsang, Georgia B.
PY - 1992/9/3
Y1 - 1992/9/3
N2 - To the Editor: In their study of the use of thalidomide in the treatment of graft-versus-host disease (GVHD), Vogelsang et al. (April 16 issue)1 minimize the seriousness of thalidomide neuropathy. Follow-up studies of patients who took thalidomide as a sedative have shown that, even several years after the drug had been stopped, there was no recovery of sensation in 50 percent of cases.2 The total amount of drug ingested determines the severity of the neuropathy.2 Therefore, any neuropathy that occurs in patients being treated for GVHD is likely to be very severe, since the daily dose of 800 to 1600…
AB - To the Editor: In their study of the use of thalidomide in the treatment of graft-versus-host disease (GVHD), Vogelsang et al. (April 16 issue)1 minimize the seriousness of thalidomide neuropathy. Follow-up studies of patients who took thalidomide as a sedative have shown that, even several years after the drug had been stopped, there was no recovery of sensation in 50 percent of cases.2 The total amount of drug ingested determines the severity of the neuropathy.2 Therefore, any neuropathy that occurs in patients being treated for GVHD is likely to be very severe, since the daily dose of 800 to 1600…
UR - http://www.scopus.com/inward/record.url?scp=0026802993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026802993&partnerID=8YFLogxK
U2 - 10.1056/NEJM199209033271016
DO - 10.1056/NEJM199209033271016
M3 - Letter
C2 - 1323060
AN - SCOPUS:0026802993
SN - 0028-4793
VL - 327
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 10
ER -